VIP neurotrophism in the central nervous system: Multiple effecters and identification of a femtomolar-acting neuroprotective peptide

Douglas E. Brenneman, Gordon Glazner, Joanna M. Hill, Janet Hauser, Ariane Davidson, Illana Gozes

Research output: Contribution to journalArticlepeer-review

Abstract

Vasoactive intestinal peptide has neurotrophic and growth-regulating properties. As in the case of many neurotrophic molecules, VIP also has neuroprotective properties, including the prevention of cell death associated with excitotoxicity (NMDA), beta amyloid peptide, and gp120, the neurotoxic envelope protein from the human immunodeficiency virus. The neurotrophic and neuroprotective properties are mediated in part through the action of glial-derived substances released by VIP. These substance include cytokines, protease nexin I, and ADNF, a novel neuroprotective protein with structural similarities to heat-shock protein 60. Antiserum against ADNF produced neuronal cell death and an increase in apoptotic neurons in cell culture. A 14 amino acid peptide (ADNF-14) derived from ADNF has been discovered that mimics the survival-promoting action of the parent protein. These studies support the conclusion that VIP, PACAP, and associated molecules are both important regulators of neurodevelopment and strong candidates for therapeutic development for the treatment of neurodegenerative disease.

Original languageEnglish
Pages (from-to)207-212
Number of pages6
JournalAnnals of the New York Academy of Sciences
Volume865
DOIs
StatePublished - 1998

Fingerprint

Dive into the research topics of 'VIP neurotrophism in the central nervous system: Multiple effecters and identification of a femtomolar-acting neuroprotective peptide'. Together they form a unique fingerprint.

Cite this